<DOC>
	<DOCNO>NCT01795781</DOCNO>
	<brief_summary>New anticoagulant introduce replace warfarin . These drug require monitoring safer . There currently recommend way reverse drug rapidly event undue bleed need emergency surgery . This lab study look way reverse drug rapidly</brief_summary>
	<brief_title>Assays Reversal New Anticoagulants</brief_title>
	<detailed_description>We develop vitro assay measurement effect drug relevant coagulation pathway plasma ; assay widely establish . This allow u test potential reversing agent activate Factor VII ( Novo-SevenÂ® ) , Factor VIII inhibitor bypass agent ( FEIBA ) ability reverse anti-coagulants invitro . The aims reversal research strategy provide mean whereby patient present serious bleed need rapid reversal surgery , example , offer treatment allow rapid normalisation coagulation system . As part developmental programme , wish obtain sample patient receive Rivaroxaban Dabigatran therapeutic reason , test effect respective drug relevant coagulation factor test vitro reversibility . The requirement patient extra 20ml blood take time patient blood test . There risk experimental procedure plan carried patient .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Osteoarthritis , Hip</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Receiving dabigatran atrial fibrillation Or , osteoarthritis hip knee receive rivaroxaban prevent thromboembolic disease total hip knee replacement respectively Failure sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anticoagulant measurement</keyword>
	<keyword>Anticoagulant reversal</keyword>
	<keyword>Dabigatran</keyword>
	<keyword>Rivaroxaban</keyword>
</DOC>